Advertisement
Singapore markets closed

  • Straits Times Index

    3,187.66
    +32.97 (+1.05%)
     

  • S&P 500

    5,033.66
    +11.45 (+0.23%)
     

  • Dow

    37,975.59
    +222.28 (+0.59%)
     

  • Nasdaq

    15,693.64
    +10.27 (+0.07%)
     

  • Bitcoin USD

    63,690.64
    +1,683.38 (+2.71%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • FTSE 100

    7,864.93
    +16.94 (+0.22%)
     

  • Gold

    2,398.60
    +10.20 (+0.43%)
     

  • Crude Oil

    82.70
    +0.01 (+0.01%)
     

  • 10-Yr Bond

    4.6330
    +0.0480 (+1.05%)
     

  • Nikkei

    38,079.70
    +117.90 (+0.31%)
     

  • Hang Seng

    16,385.87
    +134.03 (+0.82%)
     

  • FTSE Bursa Malaysia

    1,544.76
    +4.34 (+0.28%)
     

  • Jakarta Composite Index

    7,166.81
    +35.97 (+0.50%)
     

  • PSE Index

    6,523.19
    +73.15 (+1.13%)
     

Why FibroGen (FGEN) Might Surprise This Earnings Season

Zacks Equity Research
·2-min read

Investors are always looking for stocks that are poised to beat at earnings season and FibroGen, Inc FGEN may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because FibroGen is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for FGEN in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at 23 cents per share for FGEN, compared to a broader Zacks Consensus Estimate of a loss of 30 cents per share. This suggests that analysts have very recently bumped up their estimates for FGEN, giving the stock a Zacks Earnings ESP of +1.69% heading into earnings season.

FibroGen, Inc Price and EPS Surprise

FibroGen, Inc Price and EPS Surprise
FibroGen, Inc Price and EPS Surprise

FibroGen, Inc price-eps-surprise | FibroGen, Inc Quote

ADVERTISEMENT

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that FGEN has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for FibroGen, and that a beat might be in the cards for the upcoming report.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
FibroGen, Inc (FGEN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research